Changes in non-high-density lipoprotein cholesterol levels and triglyceride/high-density lipoprotein cholesterol ratios among patients randomized to aripiprazole versus olanzapine
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Objective Non-high-density lipoprotein cholesterol (non-HDL-C) and the triglyceride to high-density lipoprotein cholesterol ratio (TG:HDL-C) are predictors of cardiovascular risk. This post-hoc analysis assessed changes in these parameters during treatment with the atypical antipsychotics olanzapine or aripiprazole using pooled data from three randomized, long-term clinical studies in patients with schizophrenia. Methods Data were pooled from one open-label and two double-blind (26- or 52-week) studies in patients randomized to olanzapine (5–20 mg/day) or aripiprazole (15–30 mg/day). Change from baseline in non-HDL-C levels between groups was analyzed in the Observed Case (OC) dataset at each time point and Last Observation Carried Forward (LOCF) dataset at endpoint using analysis of covariance, with treatment as main effect and baseline non-HDL-C as covariate. Differences between groups in median changes from baseline in TG:HDL-C were assessed with Kruskal–Wallis tests. Results This analysis included 546 patients (olanzapine, n=274; aripiprazole, n=272). Mean changes from baseline in non-HDL-C levels were significantly different (p<0.0001) with olanzapine versus aripiprazole at Weeks 26 (+13.0 vs. −7.5 mg/dL) and 52 (+12.2 vs. −8.1 mg/dL). Baseline TG:HDL-C was high in the olanzapine (3.73) and aripiprazole (3.79) groups. Differences in median changes from baseline in TG:HDL-C were significant with olanzapine versus aripiprazole at Weeks 26 (+0.22 vs. −0.54; p<0.0001) and 52 (+0.24 vs. −0.62; p=0.004). Conclusions Long-term aripiprazole treatment is associated with improvements in lipid profiles of schizophrenia patients versus no improvement or worsening during olanzapine treatment. Consideration of cardiovascular risk is needed when prescribing antipsychotics, as is close monitoring for metabolic changes during treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Consensus development conference on antipsychotic drugs and obesity and diabetes
American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, & North American Association for the Study of Obesity (2004) · Diabetes Care · doi:10.2337/diacare.27.2.596 · Cited by 1,554
Use of metabolic markers to identify overweight individuals who are insulin resistant
McLaughlin, T., Abbasi, F., Cheal, K., Chu, J., Lamendola, C., & Reaven, G. (2003) · Annals of Internal Medicine · doi:10.7326/0003-4819-139-10-200311180-00007 · Cited by 1,022
Goff, D. C., Sullivan, L. M., McEvoy, J. P., Meyer, J. M., Nasrallah, H. A., Daumit, G. L., Lamberti, S., D'Agostino, R. B., Stroup, T. S., Davis, S., et al. (2005) · Schizophrenia Research · doi:10.1016/j.schres.2005.08.010 · Cited by 528
Self-citationSevere Mental Illness and Risk of Cardiovascular Disease
Newcomer, J. W., & Hennekens, C. H. (2007) · JAMA · doi:10.1001/jama.298.15.1794 · Cited by 433 · cited 5×
“The magnitude of these effects, in a patient population known for substantial cardiometabolic risk and premature CVDmortality (Newcomer and Hennekens, 2007), is relevant to medical decisionmaking in patients requiring antipsychotic treatment and needing an intervention to lower non-HDL-C or TG:HDL-C levels (e.g., chan…”
BackgroundInfluentialSelf-citation
Cited by
Influence of antipsychotics on mortality in schizophrenia: systematic review
Weinmann, S., Read, J., & Aderhold, V. (2009) · Schizophrenia Research · doi:10.1016/j.schres.2009.05.018 · Cited by 224
“For example, while aripiprazole has been shown to be associated with an improvement in lipid profiles (Newcomer et al., 2008), reduced physical activity due to neuroleptic induced deficit syndrome (Schooler, 1994) or increased smoking intensity correlated with D2 receptor occupancy of antipsychotics (de Haan et al.”
BackgroundAripiprazole versus other atypical antipsychotics for schizophrenia
Khanna, P., Suo, T., Komossa, K., Ma, H., Rummel-Kluge, C., El-Sayeh, H. G., Leucht, S., & Xia, J. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006569.pub5 · Cited by 151
Newcomer, J. W., Eriksson, H., Zhang, P., Weiller, E., & Weiss, C. (2018) · Current Medical Research and Opinion · doi:10.1080/03007995.2018.1498779 · Cited by 25
Self-citationAntipsychotic-Induced Increase in Lipid Biosynthesis: Activation through Inhibition?
Skrede, S., Steen, V. M., & Fern⊘, J. (2013) · Journal of Lipid Research · doi:10.1194/jlr.e034736 · Cited by 23
“Unfortunately, several of the commonly used drugs, particularly the secondgeneration antipsychotics (SGAs) clozapine and olanzapine, induce metabolic disturbances such as obesity, hypertriglyceridemia, glucose dysregulation, and, in some studies, elevated serum cholesterol levels (1, 2).”
Background
Metadata
- Authors
- NEWCOMER, J., MEYER, J., BAKER, R., EUDICONE, J., PIKALOV, A., VESTERBLOKLAND, E., MCQUADE, R., CRANDALL, D., CARSON, W., & MARCUS, R.
- Venue
- Schizophrenia Research
- Publisher
- Elsevier BV
- Published
- 2008-12
- Volume
- 106
- Issue
- 2-3
- Pages
- 300-307
- ISSN
- 0920-9964 (ISSN-L)
- OpenAlex
- W2064125890
- Cited by
- 27
- References
- 4
- FWCI
- 2.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.